Immune Therapeutics, Inc. (IMUN) Expands Board of
Post# of 39
Posted On: 03/03/2016 5:37:13 PM
Immune Therapeutics, Inc. (IMUN) Expands Board of Directors
Before the opening bell, Immune Therapeutics, Inc. (OTCQB: IMUN) announced the appointment of two new members to its board of directors: Dr. Clifford A. Selsky and Paul Akin. Akin brings a wealth of financial experience developed across his prior operating and board roles to the Immune Therapeutics board, while Selsky offers a critical perspective as a scientist, physician and patient advocate. The company will look to leverage this combined experience as it continues to pursue sustainable financial growth by developing and commercializing novel, patented therapies to combat chronic, life-threatening diseases through the activation and modulation of the body’s immune system, particularly in emerging global markets.
“Paul Akin and Dr. Selsky’s breadth of knowledge and experience will provide invaluable insight to Immune as we continue to grow the business and strive to deliver innovative therapies in emerging nations,” Noreen Griffin, chief executive officer of Immune Therapeutics, stated in this morning’s news release.
The release went on to provide additional background information on the company’s new board members.
Paul Akin brings more than 25 years of leadership experience to the Immune Therapeutics board. In addition to serving as a significant investor and active strategist for the company, he has played an instrumental role in the strategic planning and coordination of market penetration, expansion and capitalization. Akin currently serves as the CEO and executive chairman of San Francisco-based Collier Warehouse Group, which has, during his tenure, recorded annual double-digit growth rates. Akin is also an active investor in a variety of emerging growth companies and has served in a number of business roles – including executive chairman, independent board director, strategic advisor, venture capital limited partner, market pundit, private investor and trustee.
Clifford A. Selsky, PhD, MD, has worked as a practicing pediatrician for the past 20 years. He earned his PhD in microbiology and molecular genetics at the University of Miami School of Medicine before completing DNA repair research studies at Harvard School of Public Health and Stanford University. After training in pediatrics at Yale New Haven Hospital and completing a pediatric hematology and oncology fellowship at Yale University School of Medicine, Selsky founded the Children’s Center of Cancer and Blood Disease at the Florida Hospital Cancer Institute. Currently, he is a pediatrician at Family First Pediatrics, which he established in 2013.
Immune Therapeutics, Inc. is a biotechnology company with a promising portfolio of products and immunotherapy technologies designed to harness the power of the immune system in order to enhance the treatment of cancer, infections such as HIV/Aids, chronic inflammatory diseases and autoimmune diseases. The company is currently pursuing investigations of its most advanced clinical programs – including met-enkephalin (MENK) and low dose naltrexone (LDN), or Lodonal™ – as viable treatments for a variety of underserved indications.
Learn more by visiting www.immunetherapeutics.com
Please see disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.com
Before the opening bell, Immune Therapeutics, Inc. (OTCQB: IMUN) announced the appointment of two new members to its board of directors: Dr. Clifford A. Selsky and Paul Akin. Akin brings a wealth of financial experience developed across his prior operating and board roles to the Immune Therapeutics board, while Selsky offers a critical perspective as a scientist, physician and patient advocate. The company will look to leverage this combined experience as it continues to pursue sustainable financial growth by developing and commercializing novel, patented therapies to combat chronic, life-threatening diseases through the activation and modulation of the body’s immune system, particularly in emerging global markets.
“Paul Akin and Dr. Selsky’s breadth of knowledge and experience will provide invaluable insight to Immune as we continue to grow the business and strive to deliver innovative therapies in emerging nations,” Noreen Griffin, chief executive officer of Immune Therapeutics, stated in this morning’s news release.
The release went on to provide additional background information on the company’s new board members.
Paul Akin brings more than 25 years of leadership experience to the Immune Therapeutics board. In addition to serving as a significant investor and active strategist for the company, he has played an instrumental role in the strategic planning and coordination of market penetration, expansion and capitalization. Akin currently serves as the CEO and executive chairman of San Francisco-based Collier Warehouse Group, which has, during his tenure, recorded annual double-digit growth rates. Akin is also an active investor in a variety of emerging growth companies and has served in a number of business roles – including executive chairman, independent board director, strategic advisor, venture capital limited partner, market pundit, private investor and trustee.
Clifford A. Selsky, PhD, MD, has worked as a practicing pediatrician for the past 20 years. He earned his PhD in microbiology and molecular genetics at the University of Miami School of Medicine before completing DNA repair research studies at Harvard School of Public Health and Stanford University. After training in pediatrics at Yale New Haven Hospital and completing a pediatric hematology and oncology fellowship at Yale University School of Medicine, Selsky founded the Children’s Center of Cancer and Blood Disease at the Florida Hospital Cancer Institute. Currently, he is a pediatrician at Family First Pediatrics, which he established in 2013.
Immune Therapeutics, Inc. is a biotechnology company with a promising portfolio of products and immunotherapy technologies designed to harness the power of the immune system in order to enhance the treatment of cancer, infections such as HIV/Aids, chronic inflammatory diseases and autoimmune diseases. The company is currently pursuing investigations of its most advanced clinical programs – including met-enkephalin (MENK) and low dose naltrexone (LDN), or Lodonal™ – as viable treatments for a variety of underserved indications.
Learn more by visiting www.immunetherapeutics.com
Please see disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.com
(0)
(0)Biostax Corp. (BTAX) Stock Research Links
Scroll down for more posts ▼